FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

U.S. health advisers are considering a new flu vaccine from Moderna that uses mRNA technology, the same method that helped combat COVID-19. This vaccine, called mFlusiva, is aimed at people aged 50 and older. The FDA is reviewing it for approval before the winter flu season. mRNA vaccines can be produced more quickly, which is beneficial if the flu virus mutates unexpectedly. In a study of 40,000 people, Moderna’s vaccine reduced flu cases by 27% compared to another common vaccine. The FDA has reviewed the data positively, with no safety concerns. If approved, Moderna plans further studies involving 400,000 seniors. The ability to rapidly produce vaccines that match current flu strains could significantly reduce hospitalizations. The FDA is considering approval despite some data gaps, following a previous dispute over study comparisons. QUESTION: How might the introduction of mRNA flu vaccines change the way we respond to future flu seasons?